<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="1586">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    https://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 13, 2016</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01712711</url>
  </required_header>
  <id_info>
    <org_study_id>1391/7/24-579</org_study_id>
    <nct_id>NCT01712711</nct_id>
  </id_info>
  <brief_title>Helicobacter Pylori Eradication in Diabetic Subjects With Non-alcoholic Fatty Liver Disease</brief_title>
  <official_title>The Effect of Helicobacter Pylori Eradication on Liver Fat Content in Diabetic Subjects With Non-alcoholic Fatty Liver Disease</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Tehran University of Medical Sciences</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Tehran University of Medical Sciences</source>
  <oversight_info>
    <authority>Iran: Ministry of Health</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of study was to evaluate the effect of helicobacter pylori eradication on liver fat
      content, liver function tests, lipid profile, homeostasis model assessment-IR (HOMA-IR)
      index, and anthropometric measurements (body mass index and waist circumference)in diabetic
      subjects with non-alcoholic fatty liver disease.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Helicobacter pylori (HP) antigens have been found in the liver of individuals with benign
      and malignant liver diseases. The role of HP in the pathogenesis of non-alcoholic fatty
      liver disease (NAFLD) is controversial.

      This randomized double blind clinical trial was performed in diabetic dyspeptic patients
      with positive antibody to HP and the evidence of fatty liver in ultrasonography. After
      excluding other causes, participants with persistent elevated serum aminotransferase levels
      were presumed to have NAFLD. Those with NAFLD liver fat score greater than (-0.64) and
      positive urea breath test (UBT) were enrolled. They were randomly assigned to lifestyle
      modification alone or lifestyle modification plus HP eradication groups. Quadruple therapy
      (omeprazole, amoxicillin, bismuth subcitrate, and clarithromycin) for HP eradication was
      performed in two weeks. HP eradication was documented by UBT. Liver fat content, fasting
      serum glucose, alanine aminotransferase, aspartate aminotransferase, alkaline phosphatase,
      triglyceride, cholesterol, high and low-density lipoprotein, HOMA-IR, and anthropometric
      measurements (body mass index and waist circumference) were checked at baseline and six
      weeks post-treatment.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>September 2012</start_date>
  <completion_date type="Actual">March 2013</completion_date>
  <primary_completion_date type="Actual">February 2013</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Caregiver, Outcomes Assessor), Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Liver Fat Content Change From Baseline to Six Weeks Post H.Pylori Treatment</measure>
    <time_frame>8 weeks</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">40</enrollment>
  <condition>Non-alcoholic Fatty Liver Disease</condition>
  <arm_group>
    <arm_group_label>Lifestyle modification</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Obtaining ideal body weight by calorie restriction diet and programmed physical activity</description>
  </arm_group>
  <arm_group>
    <arm_group_label>H.pylori eradication</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>H.pylori eradication by quadruple antibiotic therapy for two weeks plus obtaining ideal body weight by calorie restriction diet and programmed physical activity</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>H.pylori eradication</intervention_name>
    <description>The regimen consists of Omeprazole (20 mg/BD)+ Amoxicillin (1 g/day)+ Bismuth subcitrate (240 mg/BD)+ Azithromycin (500 mg/BD)for two weeks</description>
    <arm_group_label>H.pylori eradication</arm_group_label>
    <other_name>Helicobacter pylori treatment</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Diabetic dyspeptic patients with positive antibody to H.pylori and persistent
             elevated aminotransferase levels with the evidence of fatty liver in ultrasonography,
             who were referred to a gastroenterology clinic

        Exclusion Criteria:

          -  Alcohol use (more than 20 gram per day in men and 10 gram per day in women per day),
             heart disease (ischemic or congestive), hepatic disease (viral hepatitis, autoimmune
             hepatitis, wilson disease, hemochromatosis, liver mass lesion), renal disease (serum
             creatinine concentration of &gt; 1.5 mg/dl), any severe systemic co-morbidities,
             neoplasm, using any hepatotoxic medication during the past 3 months, previous history
             of peptic ulcer, previous history of H.pylori eradication, existence of alarm signs
             (weight loss, dysphagia, anemia, vomiting, positive family history of
             gastrointestinal cancers), and pregnant or lactating women.
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Raika Jamali, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Tehran University of Medical Sciences</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Gastroenterology clinic, Sina Hospital</name>
      <address>
        <city>Tehran</city>
        <country>Iran, Islamic Republic of</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Iran, Islamic Republic of</country>
  </location_countries>
  <verification_date>March 2013</verification_date>
  <lastchanged_date>March 21, 2013</lastchanged_date>
  <firstreceived_date>October 19, 2012</firstreceived_date>
  <firstreceived_results_date>March 21, 2013</firstreceived_results_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Tehran University of Medical Sciences</investigator_affiliation>
    <investigator_full_name>Raika Jamali</investigator_full_name>
    <investigator_title>Assistant Professor of Medicine</investigator_title>
  </responsible_party>
  <keyword>Steatohepatitis,</keyword>
  <keyword>Helicobacter pylori,</keyword>
  <keyword>Insulin resistance,</keyword>
  <keyword>Alanine aminotransferase,</keyword>
  <keyword>Aspartate aminotransferase,</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Fatty Liver</mesh_term>
    <mesh_term>Liver Diseases</mesh_term>
  </condition_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Lifestyle Modification</title>
          <description>Obtaining ideal body weight by calorie restriction diet and programmed physical activity</description>
        </group>
        <group group_id="P2">
          <title>H.Pylori Eradication</title>
          <description>H.pylori eradication by quadruple antibiotic therapy for two weeks plus obtaining ideal body weight by calorie restriction diet and programmed physical activity</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="20"/>
                <participants group_id="P2" count="20"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="20"/>
                <participants group_id="P2" count="20"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Lifestyle Modification</title>
          <description>Obtaining ideal body weight by calorie restriction diet and programmed physical activity</description>
        </group>
        <group group_id="B2">
          <title>H.Pylori Eradication</title>
          <description>H.pylori eradication by quadruple antibiotic therapy for two weeks plus obtaining ideal body weight by calorie restriction diet and programmed physical activity</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <measure_list>
        <measure>
          <title>Number of Participants</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <measurement_list>
                <measurement group_id="B1" value="20"/>
                <measurement group_id="B2" value="20"/>
                <measurement group_id="B3" value="40"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <sub_title>&lt;=18 years</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="0"/>
                <measurement group_id="B2" value="0"/>
                <measurement group_id="B3" value="0"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>Between 18 and 65 years</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="20"/>
                <measurement group_id="B2" value="20"/>
                <measurement group_id="B3" value="40"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>&gt;=65 years</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="0"/>
                <measurement group_id="B2" value="0"/>
                <measurement group_id="B3" value="0"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <category_list>
            <category>
              <measurement_list>
                <measurement group_id="B1" value="39.95" spread="9.53"/>
                <measurement group_id="B2" value="45.73" spread="12.54"/>
                <measurement group_id="B3" value="42.84" spread="11.04"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <sub_title>Female</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="8"/>
                <measurement group_id="B2" value="12"/>
                <measurement group_id="B3" value="20"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>Male</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="12"/>
                <measurement group_id="B2" value="8"/>
                <measurement group_id="B3" value="20"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <sub_title>Iran, Islamic Republic of</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="20"/>
                <measurement group_id="B2" value="20"/>
                <measurement group_id="B3" value="40"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Liver Fat Content Change From Baseline to Six Weeks Post H.Pylori Treatment</title>
        <time_frame>8 weeks</time_frame>
        <safety_issue>No</safety_issue>
        <group_list>
          <group group_id="O1">
            <title>Lifestyle Modification</title>
            <description>Obtaining ideal body weight by calorie restriction diet and programmed physical activity</description>
          </group>
          <group group_id="O2">
            <title>H.Pylori Eradication</title>
            <description>H.pylori eradication by quadruple antibiotic therapy for two weeks plus obtaining ideal body weight by calorie restriction diet and programmed physical activity</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="20"/>
                  <measurement group_id="O2" value="19"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Liver Fat Content Change From Baseline to Six Weeks Post H.Pylori Treatment</title>
            <units>percentage of liver fat content</units>
            <param>Mean</param>
            <dispersion>Standard Deviation</dispersion>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="2.46" spread="2.23"/>
                  <measurement group_id="O2" value="3.61" spread="3.25"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Lifestyle Modification</title>
          <description>Obtaining ideal body weight by calorie restriction diet and programmed physical activity</description>
        </group>
        <group group_id="E2">
          <title>H.Pylori Eradication</title>
          <description>H.pylori eradication by quadruple antibiotic therapy for two weeks plus obtaining ideal body weight by calorie restriction diet and programmed physical activity</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>No limitation existed.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Professor Raika Jamali</name_or_title>
      <organization>Tehran University of Medical Sciences</organization>
      <phone>00982163120000 ext 411</phone>
      <email>jamalira@tums.ac.ir</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>
